BIO · NYSE · STOCK
Bio-Rad Laboratories (BIO) Stock Analysis
$366.14
52W $236.73 – $396.23
61/100
$9.86B
44.0
1.07
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Is BIO Bullish or Bearish?
Bullish.
Innellis AI committee rates Bio-Rad Laboratories (BIO) Buy with a composite score of 61/100
, based on 6 analysts with 50% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +14.10 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -5.90 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Risk Analyst sees a compelling case — low leverage (debt-to-equity 0.16) -- balance sheet can absorb a shock. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Price-to-book of 1.1x is a discount to asset value — Value
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
- Low leverage (debt-to-equity 0.16) -- balance sheet can absorb a shock — Risk
- News sentiment is positive (+0.33 across 6 articles, 14d) — News
Bear Case
- P/E of 44.1 is expensive by classic value standards — Value
- ROE of only 3.1% -- cheap may mean cheap for a reason — Value
- EPS declining -29.6% YoY despite any revenue growth — Growth
- MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
61/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 28%
of 192 Healthcare peers
Value Analyst
neutral
50
/ 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ Price-to-book of 1.1x is a discount to asset value
− P/E of 44.1 is expensive by classic value standards
Growth Analyst
neutral
48
/ 100 · High confidence
Moderate growth -- present but not remarkable
+ Quarter-over-quarter growth rate is ACCELERATING, not just positive
− EPS declining -29.6% YoY despite any revenue growth
Technical Analyst
neutral
54
/ 100 · High confidence
Mixed or range-bound price action
+ Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement
− MACD histogram negative -- bearish momentum
Risk Analyst
bullish
80
/ 100 · Low confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
+ Low leverage (debt-to-equity 0.16) -- balance sheet can absorb a shock
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
68
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.33 across 6 articles, 14d)
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 60.9 to 60.9.
- New bearish signals: 1 appeared.
- Bearish pressure eased: 1 signal(s) disappeared.
Analyst-level changes:
- Value Analyst: +1 bearish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
44.3
Neutral
MACD Histogram
-2.355
Bearish Momentum
Trend Direction
Sideways
Weekly: Sideways
Market Structure
Hh Hl
Support
$357.10
Resistance
$371.12
Bollinger %B
0.23
Inside Bands
Price vs Moving Averages
EMA 9
$369.31
Below
EMA 21
$372.16
Below
EMA 50
$362.91
Above
EMA 200
$322.25
Above
Fundamental Analysis
Valuation
67
Growth
68
Profitability
61
Financial Health
100
Cash Flow
70
Valuation
P/E Ratio
44.0×
P/B Ratio
1.37×
PEG Ratio
-0.15
Dividend Yield
0.00%
52W High
$396.23
52W Low
$236.73
Quality & Growth
ROE
1019.5%
ROA
718.5%
Gross Margin
5189.8%
Operating Margin
907.6%
Revenue Growth YoY
—
Debt / Equity
0.17
AI Fundamental Assessment
P/E ratio of 44.0 (rich relative to a 15-40x range); Price-to-book of 1.4x; PEG ratio of -0.1 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 10.2%; Return on assets of 7.2%; Net margin of 8.6%; Gross margin of 51.9%; Current ratio of 3.14 (healthy short-term liquidity); Debt-to-equity of 0.17; Free cash flow per share is positive (13.20); Most recent quarter beat estimates by 48.4%; EPS growth accelerating (-24.7% -> +38.6% QoQ); Average YoY EPS growth of 0.4%; Analyst estimates falling over recent quarters
Get the Full BIO Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →